Suscribirse

Insulin-like growth factors and cancer - 01/09/11

Doi : 10.1016/S1470-2045(02)00731-3 
Gregor Fürstenberger, Dr a,  : Senior Oncology Research Fellow, Hans-Jörg Senn b : Professor and Chairman
a Medical Oncology, Center for Tumour Detection and Prevention, St Gallen, Switzerland 
b Center for Tumour Detection and Prevention, St Gallen, Switzerland 

* Correspondence: Dr Gregor Fürstenberger, Senior Oncology Research Fellow, Center for Tumour Detection and Prevention, Rorschacherstrasse 150, CH-9006 St. Gallen, Switzerland. Tel: + 41 71 243 0043. Fax: + 41 71 243 0044

Summary

Interest in insulin-like growth factors (IGFs) and their effect on carcinogenesis has increased recently because high serum concentrations of IGF1 are associated with an increased risk of breast, prostate, colorectal, and lung cancers. Physiologically, IGF1 is the major mediator of the effects of the growth hormone; it thus has a strong influence on cell proliferation and differentiation and is a potent inhibitor of apoptosis. The action of IGF1 is predominantly mediated through the IGF1 receptor (IGF1R). IGF1R is involved in several oncogenic transformation processes. The availability of unbound IGF1 for interaction with IGF1R is modulated by IGF-binding proteins (IGFBP1–6). IGFBPs, especially IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2002  Elsevier Ltd. Reservados todos los derechos.© 2002  Courtesy of AG Renehan, CRC Paterson Institute for Cancer Research, UK. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 2002  1997 Massachusetts Medical Society. All rights reserved. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 2002  Courtesy of BioCarta. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 3 - N° 5

P. 298-302 - mai 2002 Regresar al número
Artículo precedente Artículo precedente
  • A case for geriatric oncology
  • Lazzaro Repetto, Lodovico Balducci
| Artículo siguiente Artículo siguiente
  • Hormone-replacement therapy and breast cancer
  • Jo Marsden

¿Ya suscrito a @@106933@@ revista ?